MedTrace Logo

Caelyx Biweekly in Heavily Pretreated Patients With Relapsed Ovarian Cancer

NCT00170573 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 77

Last updated 2024-12-16

Study results available
· View outcomes & findings →

Summary

Effect of biweekly schedule of PLD on dose-limiting toxicity of PPE and patient's quality of life

Conditions

Interventions

DRUG

Caelyx

40 mg/m² biweekly

Sponsors & Collaborators

  • North Eastern German Society of Gynaecological Oncology

    lead OTHER

Principal Investigators

  • Jalid Sehouli · Charite University, Berlin, Germany

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-09-30
Primary Completion
2009-04-30
Completion
2010-08-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00170573 on ClinicalTrials.gov